[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wei Zhao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100350557",false,"NCT03844360","Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease","Inclusion Criteria:\n\n* Patients must be diagnosed with hematological neoplasms\n* Antineoplastic drugs or anti-infective drugs used as part of regular treatment\n\nExclusion Criteria:\n\n* expected survival time less than the treatment cycle;\n* patients with other factors that researcher considers unsuitable for inclusion.","ALL","1 Day","18 Years",{"count":18,"type":19},1500,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.",[25],"Hematological Neoplasms","RECRUITING","2025-03-25",{"date":29,"type":30},"2025-03-30","ACTUAL",{"date":32,"type":30},"2016-01-31",{"date":34,"type":19},"2026-12-31",{"name":36,"class":37},"Wei Zhao","OTHER",{"id":39,"slug":4,"hasResults":10,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":10,"sex":14,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":48,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100474568","NCT05459597","Antiepileptic Drugs in Elderly Patients","Population Pharmacokinetics, Effectiveness and Safety of Antiepileptic Drugs in Elderly Patients","Inclusion Criteria:\n\n1. Age ≥65 years old;\n2. Diagnosed with epilepsy;\n3. Using antiepileptic drugs for treatment;\n\nExclusion Criteria:\n\n1. Patients who are expected to die within 48 hours;\n2. Patients with allergy to antiepileptic drugs;\n3. Patients receiving other investigational drugs;\n4. Other factors that the researcher considers unsuitable for inclusion.","65 Years","100 Years",{"count":47,"type":19},500,"3 Days","OBSERVATIONAL","The purpose is to study the population pharmacokinetics, effectiveness and safety of antiepileptic drug (phenytoin, carbamazepine, lamotrigine, levetiracetam, parempanel, etc) in elderly patients and recommend optimized dosage regimens.",[52],"Seizure, Epileptic","2022-07-14",{"date":55,"type":30},"2022-07-15",{"date":57,"type":30},"2021-01-01",{"date":59,"type":19},"2028-06-30",{"name":36,"class":37},1,""]